Revenue came in below the published bar. Second-quarter revenue was $20.7 million, down 21% year over year and roughly 7% below the published consensus of about $22.24 million. The decline mainly reflects the absence of last year’s $7.5 million licensing revenue; recurring Viatris collaboration revenue still increased to $20.7 million from $18.7 million. (Income Statement)
| Metric | Q2 2026 | Q2 2025 / expectation |
|---|---|---|
| Total revenue | $20.7 million (Income Statement) | $26.2 million prior year; ~$22.24 million consensus |
| GAAP net income (loss) | $(5.9) million (Income Statement) | $54.8 million prior year |
| GAAP diluted EPS | $(0.11) (Income Statement) | $1.08 prior year |
| Non-GAAP net income | $9.5 million (Non-GAAP reconciliation) | $(4.2) million prior year |
| YUPELRI net sales | $70.7 million (YUPELRI net sales table) | $66.3 million prior year |
| Cash and short-term marketable securities | $387.7 million (Balance Sheet) | $315.4 million at December 31, 2025 |
The underlying commercial asset remained solid. YUPELRI net sales rose 6.5% year over year to $70.7 million, implying Theravance’s 35% share increased to $24.7 million. (YUPELRI net sales table) That supports the durability of the royalty stream, but the growth was not enough to offset the lapping of the prior-year licensing payment.
Headline profitability was distorted by transaction and restructuring charges. The company recorded $6.1 million of transaction-related expense and $4.0 million of restructuring expense, contributing to an $8.3 million operating loss. (Income Statement) Excluding those items and other listed adjustments, non-GAAP net income was $9.5 million, or approximately $0.18 per share based on the basic share count. (Non-GAAP reconciliation) That is materially better than the GAAP result, but the adjustment-heavy quarter makes the headline earnings comparison less clean.
The acquisition update adds little new information. The $17.00-per-share cash offer plus an ampreloxetine CVR was announced on June 29, 2026, so the filing largely repeats an already-public transaction rather than changing the deal economics. (Corporate update) The key remaining value is the uncertain CVR: shareholders receive 80% of future net proceeds from any ampreloxetine monetization over ten years, but the filing does not establish when or whether those proceeds will materialize. (Corporate update)
Net read: mixed versus expectations. The revenue shortfall and GAAP loss weigh against the filing, while higher YUPELRI sales, a stronger adjusted result, and substantial liquidity provide offsets. With the Zymeworks transaction already known, the quarter does not materially improve the core earnings picture, but it also does not undermine the cash-backed deal value.
Read the original 8-K on SEC EDGAR ↗